Difference between revisions of "Cyclophosphamide (Cytoxan)"
Jump to navigation
Jump to search
m |
m |
||
| Line 28: | Line 28: | ||
*[[Thymoma]] | *[[Thymoma]] | ||
*[[Transplant conditioning regimens]] | *[[Transplant conditioning regimens]] | ||
| + | *[[Waldenström macroglobulinemia]] | ||
==Patient drug information== | ==Patient drug information== | ||
| Line 130: | Line 131: | ||
[[Category:Thymoma medications]] | [[Category:Thymoma medications]] | ||
[[Category:Transplant medications]] | [[Category:Transplant medications]] | ||
| + | [[Category:Waldenström macroglobulinemia medications]] | ||
[[Category:Drugs FDA approved in 1959]] | [[Category:Drugs FDA approved in 1959]] | ||
Revision as of 00:03, 13 November 2014
General information
Class/mechanism: Alkylating agent; transformed primarily in the liver to active metabolites which alkylate and crosslink DNA.[1][2]
Route: IV, PO
Extravasation: irritant, n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape,UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Acute lymphocytic leukemia
- Aggressive Non-Hodgkin lymphoma
- Bladder cancer
- Bone cancer
- Breast cancer
- Central nervous system (CNS) cancer
- Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL)
- Follicular lymphoma
- HIV-associated lymphoma
- Hodgkin lymphoma
- Hodgkin lymphoma, nodular lymphocyte-predominant
- Light-chain (AL) amyloidosis
- Mantle cell lymphoma
- Marginal zone lymphoma
- Multiple myeloma
- Neuroendocrine tumors
- Prostate cancer
- Small cell lung cancer
- T-cell lymphoma
- Thymoma
- Transplant conditioning regimens
- Waldenström macroglobulinemia
Patient drug information
- Cyclophosphamide (Cytoxan) patient drug information (Chemocare)[3]
- Cyclophosphamide (Cytoxan) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 11/16/1959: initial FDA approval
Also known as
| Synonyms | |||||||
|---|---|---|---|---|---|---|---|
| Alkyloxan | Biodoxan | Carloxan | Ciclofosfamida | Ciclofosfamida Filaxis | Ciclofosfamida Martian | Ciclokebir | Cyclam |
| Cycloblastin | Cycloblastine | Cyclo Cell | Cycloferon | Cyclomide | Cyclophar | Cyclophospham | Cyclophosphamid |
| cyclophosphamide monohydrate | Cyclophosphamid Farmos | Cyclophosphan | Cyclophosphan Lens | Cyclostin | Cycloxan | Cycram | Cydoxan |
| Cyklofosfamid | Cytophosphan | Cytoxan | Cytoxan Lyophilized | Endoxan | Endoxan-N | Endoxana | Endoxan Asta |
| Formitex | Genoxal | Genuxal | Hidrofosmin | Ledoxan | Ledoxina | Lyophilized Cytoxan | Neosar |
| Oncomide | Oncophos | Procytox | Revimmune | Sendoxan | Syklofosfamid | Trav Cyclophosphamide | Tymtran |
| Zycram | |||||||
References
Categories:
- Drug index
- Chemotherapy
- Intravenous Chemotherapy
- Irritant chemotherapy
- Oral Chemotherapy
- Alkylating agents
- Nitrogen mustards
- Acute lymphocytic leukemia medications
- Aggressive Non-Hodgkin lymphoma medications
- Bladder cancer medications
- Bone cancer medications
- Breast cancer medications
- Central nervous system (CNS) cancer medications
- Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL) medications
- Follicular lymphoma medications
- HIV-associated lymphoma medications
- Hodgkin lymphoma medications
- Hodgkin lymphoma, nodular lymphocyte-predominant medications
- Light-chain (AL) amyloidosis medications
- Mantle cell lymphoma medications
- Marginal zone lymphoma medications
- Multiple myeloma medications
- Neuroendocrine tumor medications
- Prostate cancer medications
- Small cell lung cancer medications
- T-cell lymphoma medications
- Thymoma medications
- Transplant medications
- Waldenström macroglobulinemia medications
- Drugs FDA approved in 1959